Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Genotype 4 (GT4) Hepatitis C Virus (HCV) in Egypt

Inclusion Criteria: * Chronic hepatitis C, genotype 4-infection (hepatitis C virus \[HCV\] ribonucleic acid \[RNA\] level greater than 1,000 IU/mL at Screening) * Subjects must meet one of the following: * Treatment-naive: Subject has never received antiviral treatment for HCV infection OR * Treatment Experienced (Prior null responders, Partial responders or Relapsers to pegylated-interferon \[pegIFN\]/RBV); * Females must be post-menopausal, of non-child bearing potential or practicing specific forms of birth control * In substudy 1, demonstrated absence of liver cirrhosis as confirmed by liver biopsy or Fibroscan * In substudy 2, evidence of liver cirrhosis as confirmed by liver biopsy or Fibroscan with Child-Pugh score less than or equal to 6 at Screening and confirmed absence of hepatocellular carcinoma Exclusion Criteria: * Females who are pregnant or breastfeeding * Positive screen for hepatitis B Surface antigen or anti-Human Immunodeficiency virus antibody * HCV genotype performed during screening indicating unable to genotype or co-infection with any other HCV genotype * abnormal laboratory tests * self-reports current drinking more than 2 drinks per day * current enrollment in another investigational study * previous treatment with a direct acting antiviral agent (DAA) containing regimen * In substudy 1, evidence of liver cirrhosis * In substudy 2, evidence of current or past Child-Pugh B or C classification and confirmed presence of hepatocellular carcinoma